Lexeo Therapeutics (NASDAQ:LXEO) COO Sells $20,903.68 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) COO Jose Manuel Otero sold 4,666 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total transaction of $20,903.68. Following the sale, the chief operating officer owned 137,482 shares in the company, valued at $615,919.36. The trade was a 3.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jose Manuel Otero also recently made the following trade(s):

• On Monday, May 18th, Jose Manuel Otero sold 1,302 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $5.07, for a total transaction of $6,601.14.

Lexeo Therapeutics Stock Performance

LXEO stock traded down $0.21 during midday trading on Wednesday, reaching $4.45. 852,557 shares of the company’s stock traded hands, compared to its average volume of 948,339. The company has a 50-day moving average price of $5.16 and a two-hundred day moving average price of $6.67. Lexeo Therapeutics, Inc. has a 52 week low of $3.60 and a 52 week high of $10.99. The firm has a market capitalization of $349.41 million, a PE ratio of -3.07 and a beta of 1.38.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its earnings results on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.04. As a group, analysts predict that Lexeo Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on LXEO shares. Wall Street Zen raised Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings cut shares of Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 25th. Chardan Capital reiterated a “buy” rating and issued a $17.00 target price on shares of Lexeo Therapeutics in a research note on Monday, May 11th. Finally, JPMorgan Chase & Co. cut their price target on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a report on Thursday, June 25th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $18.75.

Institutional Trading of Lexeo Therapeutics

A number of hedge funds have recently bought and sold shares of LXEO. Allworth Financial LP boosted its stake in Lexeo Therapeutics by 1,002.9% in the fourth quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock worth $34,000 after buying an additional 3,079 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Lexeo Therapeutics by 69.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock worth $35,000 after purchasing an additional 1,459 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in shares of Lexeo Therapeutics in the fourth quarter worth about $37,000. California State Teachers Retirement System increased its holdings in shares of Lexeo Therapeutics by 123.7% in the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock worth $39,000 after buying an additional 2,148 shares during the period. Finally, Cerity Partners LLC bought a new stake in shares of Lexeo Therapeutics in the 2nd quarter valued at about $50,000. Institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.